Ability Pharma is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. ABTL0812, the most advanced asset, is a drug candidate in phase 2 clinical trials as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin.

Deja una respuesta